Galectin-1 overexpression promotes cisplatin resistance in ovarian cancer cells and doxorubicin resistance in triple-negative breast cancer cells [13, 14], indicating the association of Galectin-1 signal transduction with cancer drug resistance. Here, LGALS1 is linked to ovarian carcinoma.